Related Experiment Videos
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells
Sander Zwaveling1, Michel P M Vierboom, Sandra C Ferreira Mota
1Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, the Netherlands.
Abstract:
Overexpression of p53 is found in approximately 50% of human cancers, making it an attractive target antigen for immunotherapy of cancer. Research in this area has thus far primarily focused on p53-specific CTLs. Although these CTLs were shown to be highly effective against p53-overexpressing tumors in vivo, immunological tolerance seems to strongly restrict the spectrum of the p53-specific CTL repertoire in p53(+/+) subjects. In view of the emerging role of CD4(+) Th (Th) cells in the antitumor response, we investigated the specificity and antitumor efficacy of the p53-specific Th response in mice. Our data show that high affinity Th cells against the naturally processed epitope p53(108-122) can be elicited in both p53(-/-) and p53(+/+) mice, indicating that the p53-specific T-cell response is not affected by tolerance at the Th level. Furthermore, p53(108-122)-specific Th cells were effective in enabling p53-specific CTLs to control the growth of p53-overexpressing tumors in vivo. Therefore, exploitation of the p53-specific Th response appears to be a highly useful aspect of immunotherapeutic strategies against cancers.
Insights
p53-specific T helper (Th) cells, unlike CTLs, are not hindered by immune tolerance and can effectively target p53-overexpressing tumors. This finding highlights the potential of Th cells in cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Cancer Immunotherapy
Background:
- p53 is overexpressed in about 50% of human cancers, making it a key target for cancer immunotherapy.
- Current research primarily focuses on p53-specific cytotoxic T lymphocytes (CTLs), but immune tolerance limits their repertoire in p53(+/+) subjects.
- CD4(+) T helper (Th) cells are increasingly recognized for their role in antitumor responses.
Purpose of the Study:
- To investigate the specificity and antitumor efficacy of the p53-specific Th cell response in a mouse model.
- To determine if the p53-specific Th cell response is affected by immunological tolerance.
Main Methods:
- Elicitation of high-affinity Th cells against the p53(108-122) epitope in p53(-/-) and p53(+/+) mice.
- Assessment of the antitumor efficacy of p53-specific Th cells in controlling p53-overexpressing tumors in vivo.
- Evaluation of the ability of p53-specific Th cells to enhance the activity of p53-specific CTLs.
Main Results:
- High-affinity p53(108-122)-specific Th cells were successfully elicited in both p53(-/-) and p53(+/+) mice.
- The p53-specific Th cell response was not significantly affected by immunological tolerance.
- p53(108-122)-specific Th cells enhanced the ability of p53-specific CTLs to control p53-overexpressing tumor growth in vivo.
Conclusions:
- The p53-specific Th cell response is a viable target for cancer immunotherapy as it bypasses immune tolerance.
- p53-specific Th cells can augment the antitumor activity of CTLs, offering a promising strategy for treating p53-overexpressing cancers.
- Exploiting the p53-specific Th response represents a valuable approach for developing novel immunotherapeutic strategies against various cancers.